AMCX three-lens brief
Evidence-based stock research on AMCX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved +4.41% yesterday. · Analyst mean target $9.83 — 19% below current (6 analysts).
- Moved +4.41% yesterday.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 13.9pp over 30 days.
- P/E of 11.6 — trading at a value multiple.
- Analyst mean target $9.83 — 19% below current (6 analysts).
AMCX closed at $12.07 (+4.41%) as of 2026-09-11. Market cap: $497.89M. P/E (trailing) 11.6. Price is above the 50-day MA and above the 200-day MA. Positives: moved +4.41% yesterday.; 50-day MA above 200-day MA (golden-cross regime); price above both.. Concerns: analyst mean target $9.83 — 19% below current (6 analysts).. Last quarter: Revenue $547.50M, net income -$21.94M, free cash flow $1.00B.
Why three lenses on AMCX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AMCXacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AMCX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AMCX brief"></iframe>